X hits on this document

468 views

0 shares

0 downloads

0 comments

68 / 170

9

DR. TEERLINK: Powered appropriately for cardiovascular endpoints?

10

DR. WOLF: Yes.

11

DR. TEERLINK: Thank you.

12

DR. BURMAN: Any questions?

13

(No response.)

14

I have some questions and I don't know who would be the best person.

1

that's largely due to cardiovascular issues, concerns about other agents along those

2

lines, and I am confused then how if we are doing a post marketing study, the post

3

marketing analysis compared to these other agents where one of the major concerns is

4

cardiovascular events, how we are going to get any information on a post marketing

5

study that's not randomized to comparing it to things where there is potential for

6

cardiovascular concern, I don't know how I am going to be comforted by that?

Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com

67

7

8

issue.

DR. WOLF: We intend to do randomized clinical assessments of this

23

the second is what other actions does it have and third is when you knockout mice for

24

DPP-4 what other problems do they end up with?

15

Some of them relate to physiology. The first question is a simple one, where does DPP-4

16

come from, which organ and related to that is, does it have any other actions and what

17

happens in knockout mice where DPP-4 is knocked out?

18

19

DR. WOLF: I would like to ask Dr. Mark Curby to come to come to the

podium please, or Dr. Garrell please. Thank you.

22

DR. BURMAN: Of course. The first is what's the source of DPP-4 and

20

21

DR. GARRELL: So I am Mark Garrell from the University of Sydney.

Could I get the questions repeated please, I think there was two or three.

Document info
Document views468
Page views468
Page last viewedTue Dec 06 19:09:04 UTC 2016
Pages170
Paragraphs7975
Words54271

Comments